Mobile Site ›
Normal View

Test ID: HMDP
Hyperimmunoglobulin M (Hyper-IgM) Defects Panel

NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.

No

Useful For Suggests clinical disorders or settings where the test may be helpful

Diagnosis of hyper-IgM syndromes, specifically X-linked hyper-IgM (HIGM1) and autosomal recessive hyper-IgM type 3 (HIGM3)

 

Evaluation of isotype class-switching defects

Profile Information A profile is a group of laboratory tests that are ordered and performed together under a single Mayo Test ID. Profile information lists the test performed, inclusive of the test fee, when a profile is ordered and includes reporting names and individual availability.

Test IDReporting NameAvailable SeparatelyAlways Performed
TBBST- and B-Cell QN by Flow CytometryYesYes
IABCImmune Assessment B Cell Subsets, BNoYes
CD40CD40 by Flow, QL, BYesYes
XHIMX-Linked Hyper IgM Syndrome, BYesYes

Method Name A short description of the method used to perform the test

Flow Cytometry

Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name

Hyper IgM Panel, B

Aliases Lists additional common names for a test, as an aid in searching

Acquired immune deficiency syndrome (AIDS)
AIDS (acquired immune deficiency syndrome)
B & T lymphocyte surface marker
B cell
B-cell
B-cell CD40 expression by flow cytometry
CD154
CD19 Count, Flow Cytometry
CD3 count, flow cytometry
CD4 count, flow cytometry
CD40 activation
CD40 ligand
CD56 Count, Flow Cytometry
CD8 count, flow cytometry
Flow cytometry, T- and B- cells
Helper suppressor ratio
Hyper IgM
Immune competence
Immune status, flow cytometry
Immunodeficiency panel, flow cytometry
Immunophenotyping-CD4 count, flow cytometry
Lymphocyte surface marker
Memory cells
Quantitative CD4 and CD8
Suppressor helper ratio
T & B lymphocyte surface marker
T cell
T- and B- cell quantitation by flow cytometry
T-cell
T-cell activation
T-helper/T-suppressor ratio
T4/T8 helper suppressor ratio

Specimen Type Describes the specimen type needed for testing

WB Sodium Heparin
Whole Blood EDTA

Specimen Required Defines the optimal specimen. This field describes the type of specimen required to perform the test and the preferred volume to complete testing. The volume allows automated processing, fastest throughput and, when indicated, repeat or reflex testing.

Three separate specimens are required-2 containing EDTA and 1 containing sodium heparin.

 

Send specimens Sunday through Thursday only. Specimens must arrive within 24 hours of draw and by 10 a.m. on Friday. Draw and package specimens as close to shipping time as possible. Ship specimens overnight.

 

For serial monitoring, we recommend that specimen draws be performed at the same time of day.

 

Specimen Type: Blood for TBBS/9336 T- and B-Cell Quantitation by Flow Cytometry and CD40/89009 B-Cell CD40 Expression by Flow Cytometry, Blood

Container/Tube: Lavender top (EDTA)          

Specimen Volume: 4 mL

Collection Instructions:

1. Send specimen in original tube. Do not aliquot.

2. Label specimen as blood for TBBS/9336 T- and B-Cell Quantitation by Flow Cytometry and CD40/89009 B-Cell CD40 Expression by Flow Cytometry, Blood.

Specimen Stability Information: Ambient <72 hours

Additional Information: Date of draw is required.

 

Specimen Type: Blood for IABC/87994 B-Cell Phenotyping Screen for Immunodeficiency and Immune Competence Assessment, Blood

Container/Tube: Lavender top (EDTA)                                                                                                          

Specimen Volume:

< or =14 years: 4 mL

>14 years: 10 mL

Collection Instructions:

1. Send specimen in original tube. Do not aliquot.

2. Label specimen as blood for IABC/87994 B-Cell Phenotyping Screen for Immunodeficiency and Immune Competence Assessment, Blood.

Specimen Stability Information: Refrigerated (preferred) 48 hours/Ambient 48 hours

Additional Information: Ordering physician name and phone number are required.

 

Specimen Type: Blood for XHIM/82964 X-Linked Hyper IgM Syndrome, Blood

Container/Tube: Green top (sodium heparin)

Specimen Volume: 4 mL

Collection Instructions: Label specimen as blood for XHIM/82964 X-Linked Hyper IgM Syndrome, Blood.

Specimen Stability Information: Ambient (preferred) 72 hours/Refrigerated 72 hours

Additional Information: Ordering physician name and phone number are required.

Specimen Minimum Volume Defines the amount of specimen required to perform an assay once, including instrument and container dead space. Submitting the minimum specimen volume makes it impossible to repeat the test or perform confirmatory or perform reflex testing. In some situations, a minimum specimen volume may result in a QNS (quantity not sufficient) result, requiring a second specimen to be collected.

TBBS/9336 T- and B-Cell Quantation by Flow Cyometry and CD40/89009 B-Cell CD40 Expression by Flow Cytometry, Blood: 2 mL; XHIM/82964 X-Linked Hyper IgM Syndrome, Blood: 1.2 mL; IABC/87994 B-Cell Phenotyping Screen for Immunodeficiency and Immune Competenc

Reject Due To Identifies specimen types and conditions that may cause the specimen to be rejected

Hemolysis

Mild OK; Gross reject

Lipemia

Mild OK; Gross reject

Icterus

NA

Other

Specimens in aliquot tubes (not in original Vacutainer)

Specimen Stability Information Provides a description of the temperatures required to transport a specimen to the laboratory. Alternate acceptable temperature(s) are also included.

Specimen TypeTemperatureTime
WB Sodium HeparinAmbient (preferred)72 hours
 Refrigerated 72 hours
Whole Blood EDTAVaries48 hours

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Hyperimmunoglobulin M (hyper-IgM) syndromes are a collection of primary humoral immunodeficiencies characterized by recurrent infections along with low serum IgG and IgA, and normal or elevated IgM. Over the course of the last several years, at least 5 genetic defects have been shown to be associated with this group of immunodeficiencies.(1-3) These genetic defects include mutations that affect:

-The costimulatory molecule, CD40LG, induced on activated T cells

-The CD40LG receptor, CD40, expressed constitutively on B cells

-Activation-induced cytidine deaminase (AID or AICDA), involved in somatic hypermutation (SHM) and isotype class-switching

-Uracil DNA glycosylase (UNG), also involved in isotype class-switching and partially in SHM

-NF-kappa B essential modulator (NEMO), also known as IKK gamma, which modulates NF-kappa B function(2,3)

 

The mutations that occur in the CD40LG and CD40 genes are associated with X-linked hyper-IgM (type 1) and autosomal recessive hyper-IgM (type 3), respectively. Patients with mutations in either of these 2 genes are particularly prone to infections with opportunistic pathogens, such as Pneumocystis jiroveci, Cryptosporidium parvum, and Toxoplasma gondii.(4)

 

All of the hyper-IgM syndromes (except those due to UNG defects and a hitherto undefined autosomal recessive [non-type 3] hyper-IgM) are associated with defects in isotype class-switching and SHM.(4) In the undefined autosomal recessive hyper-IgM there is no SHM defect, and in UNG deficiency there is biased SHM.(4) The impairment in isotype class-switching leads to the increased IgM levels with corresponding decrease in the "switched'' immunoglobulins such as IgG, IgA, and even IgE.

 

In the adult patient, hyper-IgM syndromes can overlap clinically with common variable immunodeficiency (CVID). However, patients with CD40LG (X-linked hyper-IgM; HIGM1) and CD40 (hyper-IgM type 3; HIGM3) mutations invariably present in infancy with upper and lower respiratory tract infections and opportunistic infections as previously described. HIGM1 is the most common of all the hyper-IgM syndromes described thus far, while HIGM3 is much rarer.

 

Intermittent neutropenia is common in HIGM1 and has also been reported for HIGM3. Both diseases show significant decreases in class-switched memory (CD27+IgM-IgD-) B cells, corresponding to profound reductions in serum IgG and IgA levels. Peripheral T-cell subsets are normal, though in HIGM1 the number of CD45RO+ memory T cells is reduced. T-cell lymphocyte proliferative responses to mitogens are normal in both HIGM1 and HIGM3, while responses to specific antigen are abnormal in HIGM1 and normal in HIGM3.

 

TBBS/9336 T- and B-Cell Quantitation by Flow Cytometry and IABC/87994 B-Cell Phenotyping Screen for Immunodeficiency and Immune Competence Assessment, Blood evaluate isotype class-switching defects with identification of various memory B-cell subsets, including class-switched memory B cells. The other components of this panel include the CD40LG XHIM/82964 X-linked Hyper IgM Syndrome, Blood, and CD40/89009 B-Cell CD40 Expression by Flow Cytometry, Blood, which is the CD40 assay for HIGM3.

 

The absolute counts of lymphocyte subsets are known to be influenced by a variety of biological factors, including hormones, the environment, and temperature. The studies on diurnal (circadian) variation in lymphocyte counts have demonstrated progressive increase in CD4 T-cell count throughout the day, while CD8 T cells and CD19+ B cells increase between 8.30 a.m. and noon with no change between noon and afternoon. Natural Killer (NK)-cell counts, on the other hand, are constant throughout the day.(5) Circadian variations in circulating T-cell counts have been shown to be negatively correlated with plasma cortisol concentration.(6, 7, 8) In fact, cortisol and catecholamine concentrations control distribution and therefore, numbers of naive versus effector CD4 and CD8 T cells.(6) It is generally accepted that lower CD4-T cell counts are seen in the morning compared to the evening(9) and during summer compared to winter.(10) These data therefore indicate that timing and consistency in timing of blood collection is critical when serially monitoring patients for lymphocyte subsets.

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

The appropriate age-related reference values will be provided on the report.

Interpretation Provides information to assist in interpretation of the test results

An interpretive report will be provided.

 

The absence of CD40LG on activated T cells is consistent with X-linked hyper-IgM syndrome (HIGM1). The presence of CD40LG on activated T cells is not consistent with HIGM1. The presence of a positive and negative population for CD40LG is consistent with HIGM1 carrier status (mosaic).

 

Negative CD40-muIg staining is consistent with HIGM1. Positive CD40-muIg staining is not consistent with HIGM1. Some patients (approximately 20%) show absent (negative) staining with the CD40-muIg antibody, while there is positive staining for surface CD40LG on activated T cells. This dichotomy is due to the presence of specific mutations in the CD40LG gene that permit normal surface expression of the protein but abrogate function. Therefore, measurement of the receptor-ligand binding function using the chimeric CD40-muIg antibody improves the specificity of the assay, enabling identification of CD40LG-deficient patients who would be missed otherwise.

 

The absence of CD40LG protein expression or CD40-muIg binding is considered confirmatory for HIGM1. Genetic testing is not necessary to confirm the diagnosis, but may be performed to identify the specific mutation involved.

 

The absence of CD40 on B cells is consistent with autosomal recessive hyper-IgM type 3 (HIGM3). The presence of CD40 on B cells is not consistent with HIGM3.

 

Reduced or absent class-switched memory B cells (CD27+IgM-IgD-) is consistent with a defect in isotype class-switching. Normal numbers of class-switched memory B cells indicates the lack of an isotype class-switching defect.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

The result for the CD40LG (X-linked hyper IgM) test is only valid when there is normal expression of CD69 upon T-cell activation.

 

Reduction of class-switched memory B cells is also seen in a significant proportion of patients with common variable immunodeficiency. Clinical correlation is essential to establishing the appropriate diagnosis.

 

Timing and consistency in timing of blood collection is critical when serially monitoring patients for lymphocyte subsets. See data under Clinical Information.

Clinical Reference Provides recommendations for further in-depth reading of a clinical nature

1. Gulino AV, Notarangelo LD: Hyper-IgM syndromes. Curr Opin Rheumatol 2003;15:422-429

2. Durandy A, Peron S, Fischer A: Hyper-IgM syndromes. Curr Opin Rheumatol 2006;18:369-376

3. Lee WI, Torgerson TR, Schumacher MJ, et al: Molecular analysis of a large cohort of patient with hyper immunoglobulin M (IgM) syndrome. Blood 2005;105:1881-1890

4. Erdos M, Durandy A, Marodi L: Genetically acquired class-switch recombination defects: the multi-faced hyper-IgM syndrome. Immunol Letter 2005;97:1-6

5. Carmichael KF, Abayomi A: Analysis of diurnal variation of lymphocyte subsets in healthy subjects and its implication in HIV monitoring and treatment. 15th Intl Conference on AIDS, Bangkok, Thailand, 2004, Abstract # B11052

6. Dimitrov S, Benedict C, Heutling D, et al: Cortisol and epinephrine control opposing circadian rhythms in T-cell subsets. Blood 2009 (prepublished online March 17, 2009)

7. Dimitrov S, Lange T, Nohroudi K, Born J: Number and function of circulating antigen presenting cells regulated by sleep. Sleep 2007;30:401-411

8. Kronfol Z, Nair M, Zhang Q, et al: Circadian immune measures in healthy volunteers: relationship to hypothalamic-pituitary-adrenal axis hormones and sympathetic neurotransmitters. Pyschosomatic Medicine 1997;59:42-50

9. Malone JL, Simms TE, Gray GC, et al: Sources of variability in repeated T-helper lymphocyte counts from HIV 1-infected patients: total lymphocyte count fluctuations and diurnal cycle are important. J AIDS 1990;3:144-151

10. Paglieroni TG, Holland PV: Circannual variation in lymphocyte subsets, revisited. Transfusion 1994;34:512-516

Method Description Describes how the test is performed and provides a method-specific reference

See individual unit codes.

Day(s) and Time(s) Test Performed Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.

Monday through Friday

Do not send specimen after Thursday. Specimen must be received by 10 a.m. Friday.

Analytic Time Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.

3 days

Maximum Laboratory Time Defines the maximum time from specimen receipt at Mayo Medical Laboratories until the release of the test result

4 days

Specimen Retention Time Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

3 days

Performing Laboratory Location The location of the laboratory that performs the test

Rochester

Test Classification Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer's instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR), Investigation Use Only (IUO) product, or a Research Use Only (RUO) product.

This test was developed using an analyte specific reagent. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Medical Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

T- and B-Cell Quantitation by Flow Cytometry

86355-B cells, total count

86357-Natural killer (NK) cells, total count

86359-T cells, total count

86360-Absolute CD4/CD8 count with ratio

 

B-Cell Phenotyping Screen for Immunodeficiency and Immune Competence Assessment, Blood

88184-Flow cytometry, first marker

88185 x 7-Flow cytometry, each additional marker

 

B-Cell CD40 Expression by Flow Cytometry, Blood

88184

 

X-Linked Hyper IgM Syndrome, Blood

88184-Flow cytometry, cell surface, cytoplasmic

88185 x 6-Each additional marker

LOINC® Code Information Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the result codes returned for this test or profile.

Result IDReporting NameLOINC Code
89009CD40 by Flow, QL, BIn Process
30296CD19+ % of total Lymphocytes8117-4
9336T-and B-Cell QN by Flow Cytometry(TBBS_)In Process
82964CD40 Ligand ExpressionIn Process
29040CD40muIg (Function)In Process
29094CD20+ % of total Lymphocytes8119-0
3321CD45 Lymph Count, Flow27071-0
3316% CD3 (T Cells)8124-0
30298CD27+ % of CD19+ B cellsIn Process
23901Interpretation69052-9
3318% CD19 (B Cells)8117-4
30300CD27+ IgM+ IgD+ % of CD19+ B cellsIn Process
30302CD27+ IgM- IgD- % of CD19+ B cellsIn Process
4054% CD16+CD56 (NK cells)18267-5
3319% CD4 (Helper Cells)8128-1
30304CD27+ IgM+ IgD- % of CD19+ B cellsIn Process
3320% CD8 (Supp'r Cells)8138-0
30306IgM+ % of CD19+ B cellsIn Process
30308CD38+ IgM- % of CD19+ B cellsIn Process
3322CD3 (T Cells)8122-4
30310CD38+ IgM+ % of CD19+ B cellsIn Process
3324CD19 (B Cells)8116-6
4055CD16+CD56 (NK cells)20402-4
30312CD21+ % of CD19+ B cellsIn Process
30314CD21- % of CD19+ B cellsIn Process
3325CD4 (Helper Cells)8127-3
3326CD8 (Supp'r Cells)8137-2
30297CD19+8116-6
29095CD20+9558-8
3327H/S Ratio8129-9
30299CD27+In Process
6657Comment48767-8
30301CD27+ IgM+ IgD+In Process
30303CD27+ IgM- IgD-In Process
30305CD27+ IgM+ IgD-In Process
30307IgM+In Process
30309CD38+ IgM-In Process
30311CD38+ IgM+In Process
30313CD21+25164-5
30315CD21-In Process
30316Interpretation69048-7